Risankizumab (trade name Skyrizi) effective for plaque psoriasis - MD Magazine - Toronto Dermatology Centre
Call Us Today: 416.633.0001
Call Us Today:416.633.0001
Risankizumab (trade name Skyrizi) effective for plaque psoriasis – MD Magazine

Risankizumab (trade name Skyrizi) effective for plaque psoriasis – MD Magazine

nurse working in medical laboratory. Model signs the model release

Long-term results from the phase 3 IMMhance study of risankizumab (Skyrizi) in patients with psoriasis indicated that a significant number of patients receiving risankizumab maintained complete skin clearance at week 94.

“Results show that Skyrizi has the potential to provide long-term relief from the signs and symptoms of psoriasis,” said Marek Honczarenko, MD, PhD, vice president, immunology development, AbbVie.

In this study, patients who reached a score of clear or almost clear on the static Physician Global Assessment (sPGA 0/1) at week 28 were randomized to either continue on risankizumab or placebo. Of those with continuous treatment with risankizumab, 73% achieved a sPGA of 0 and 72% reached a 100% improvement in the Psoriasis Area and Severity Index (PASI 100).

Read more about the study.

Credt: www.mdmag.com

Sorry, comments are closed for this post.

Subscribe to Our Newsletter

Make an Inquiry

preloader